Blake Bradford, PharmD, BCPS
@blakebradford.bsky.social
It drops enterococcal coverage but wouldn’t be high on my priority list. Possibly not worth the risk of exposing the patient to 2 new agents they could have adverse reactions too.
December 16, 2024 at 9:11 PM
It drops enterococcal coverage but wouldn’t be high on my priority list. Possibly not worth the risk of exposing the patient to 2 new agents they could have adverse reactions too.